Sector News

Emerging markets drugs worth $3B could be next on Takeda’s chopping board: report

January 22, 2019
Life sciences

Looking to trade in some assets outside Japan to fund its $58 billion takeover of Shire, Takeda is reportedly eyeing a sale of some emerging-market drugs it gained in another acquisition eight years ago.

The Japanese pharma is weighing the sale of some emerging markets products that could fetch about $3 billion, Bloomberg reported, citing people familiar with the matter. The talks are too early to draw any conclusion on the fate of specific drugs, the report said.

Takeda acquired these drugs—prescription and over-the-counter included—in its $14 billion buyout of Swiss drugmaker Nycomed in 2011. But lately, emerging markets haven’t been doing the company much good.

For the two quarters ended Sept. 30, Takeda grew sales in emerging markets by only 2.4%. That’s the lowest growth rate among all of Takeda’s geographic regions, excluding currency fluctuations and one-time changes. Taking those into account, the portfolio declined 6.6% to 126.7 billion Japanese yen ($1.16 billion). In fact, without the double-digit growth posted in China, its emerging markets decline would be even worse.

And Takeda is scouting around for assets to sell. With the Shire deal, Takeda landed a spot among the world’s 10 largest biopharma firms, but at the same time took on an additional $31 billion in debt—one of the risks cited by some buyout opponents.

To help fill that debt hole, CEO Christophe Weber has laid out plans to cut jobs in a bid to save $1.4 billion per year, and he’s also looking to unload $10 billion in assets.

So far, some Shire drugs potentially worth $4 billion to $5 billion, including dry eye therapy Xiidra, have reportedly made its for-sale list. The company has also promised to sell inflammatory bowel disease candidate SHP647 to allay EU antitrust concerns about an overlap with Takeda’s own bowel drug Entyvio. While its European OTC business could also be jettisoned, during an investor briefing in January, Weber affirmed his commitment to Takeda’s Japan-based OTC business.

In addition to those products, Takeda has unveiled a plan to shutter its Chicago-area U.S. headquarters and relocate its U.S. operations closer to Shire’s in the Boston region. And after a move to its new global headquarters in Tokyo, it’s aiming to collect around $540 million by selling its legacy Osaka estate. Meanwhile, it has returned its majority stake in a Chinese joint venture to partner Shanghai Pharma for $280 million.

By Angus Liu

Source: Fierce Pharma

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach